The frustration in advocating for universal policies and mandating insurance coverage for the treatment of patients with adiposity-based chronic disease (ie, morbid obesity) is fueled by the lack of high-quality long-term data. Are weight loss and remission of metabolic syndrome durable? Are there subsequent disease states or concerns brought on by our current interventions? The Longitudinal Assessment of Bariatric Surgery (LABS) consortium, funded by the National Institute of Diabetes and Digestive and Kidney Diseases with the assistance of the National Institutes of Health Office of Research on Women’s Health, represents the third installment of a large, extensive database with reported 82.9% of study participant follow-up at 7 years.1 Outcomes are consistent with other population-based studies, such as the Swedish Obese Subjects trial2 and Utah Obesity Study.3
Higa KD, Himpens J. The Reality of Long-term Follow-up of Bariatric/Metabolic Surgery Patients—A Conundrum. JAMA Surg. 2018;153(5):435. doi:10.1001/jamasurg.2017.5010
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: